Both gumokimab and manfidokimab met their primary endpoints, as Akeso oversees NDAs with the NMPA for both drugs.

Coya Therapeutics has announced the acceptance by the US FDA of IND application for COYA 302, paving the way for a Phase II ...

WCG has introduced Total Training, a clinical trial solution designed to reduce protocol deviations and enhance site ...

Lighthouse secured a grant of $49.2m from the National Institute on Aging (NIA) to facilitate study of LHP588 for Alzheimer's ...

BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate ...

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in ...

Dynavax has revealed outcomes from the initial part of its Phase I/II trial, comparing its shingles vaccine Z-1018 against ...

The FDA has announced it will no longer accept clinical trials that involve sending US patients cells from US to China for ...

Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 trial of ...

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.